( -limiting toxicity (DLT)was evaluated ...)New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting,Health

-limiting toxicity (DLT) was evaluated based on the first cycle of treatment and DLT was not reached in 21 patients who received the combination regimen including patients who received the full FDA approved doses of each agent. Further, all patients' platelet and neutrophil counts recovered to protocol defined levels and times allowing for re-treatment after cycle one. At baseline, median Gleason Score was eight, median PSA values were 162 ng/ml and 43% of patients had previously received taxane-based chemotherapy. Following treatment, 12 out of 21 patients achieved a 50% or greater decline in PSA. Data on progression-free survival are pending.

The authors concluded that repetitive dosing of QUADRAMET and docetaxel was feasible and well-tolerated. Clinically significant hematologic toxicity was rare and does not appear to be related to dose or disease burden. Plans are underway for a multi-center Phase 2 study with Memorial Sloan-Kettering Cancer Center and other leading prostate cancer centers.

"With bone pain representing a significant quality-of-life concern for patients with metastatic prostate cancer, we wanted to see if we could combine QUADRAMET, an FDA-approved drug to treat bone pain, with docetaxel, an FDA-approved drug to treat late stage prostate cancer, and administer both at their respective, FDA-approved therapeutic doses without compromising patient safety," explained Michael J. Morris, M.D., an oncologist specializing in prostate cancer at Memorial Sloan-Kettering Cancer Center. "The Phase 1 data demonstrate that repeated doses of QUADRAMET are safe and do not appear to impair the effective delivery of docetaxel in most patients."

"Phase 1 trial with combination of docetaxel (D) plus samarium-13 (Sm 153) in patients (pts) with hormone refractory prostate cancer (HRPC)" by Sinibaldi et al. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD (Abstract No. 15547, published in the ASCO proceedings)

Simil
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
2. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
7. VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
8. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
9. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
10. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting